Overview

Entrectinib is an orally bioavailable tyrosine kinase inhibitor that selectively targets the TRK family (NTRK1/2/3), ROS1, and ALK. Its defining feature is tissue-agnostic activity: when a tumor carries an NTRK gene fusion, the resulting constitutively active TRK fusion protein drives growth regardless of where the cancer started. By occupying the ATP-binding pocket of these kinases, entrectinib shuts down the fusion-driven proliferative signal. The 200 mg capsule therefore appeals to distributors serving both lung and solid-tumor programs under a single molecular profile, simplifying procurement for partners that manage diverse oncology portfolios.

How It Works

Entrectinib crosses the blood–brain barrier, an important property because NTRK- and ROS1-rearranged tumors can metastasize to the central nervous system. Once bound, it blocks autophosphorylation of the fusion kinase and the downstream MAPK and PI3K–AKT pathways that sustain survival. In ROS1-positive non-small cell lung cancer, this translates into meaningful intracranial control, a historically difficult goal for many targeted agents. The oral schedule also avoids the infusion infrastructure required by some older kinase inhibitors, lowering the logistical burden on treating centers.

Indications

Entrectinib is indicated for adult and pediatric patients with solid tumors that have an NTRK gene fusion and lack satisfactory alternative treatments, irrespective of primary site. It is also used in ROS1-positive metastatic non-small cell lung cancer. Patient selection rests on next-generation sequencing that demonstrates the relevant rearrangement rather than on histology alone, which is why molecular pathology collaboration is essential for correct routing to therapy.

Dosage & Administration

Dosing is based on body surface area, administered once daily, with modifications guided by neurologic, cardiac, and hepatic signals. Capsules are available in strengths that support individualized BSA-based regimens and can be opened when swallowing is difficult under pharmacy guidance.

Storage & Sourcing

Capsules ship in humidity-controlled primary packaging with secondary cold-chain cartons. GIVE LIFE TIME International supplies lot-traceable inventory and export documentation for cross-border B2B orders.

FAQ

Q: What makes entrectinib tissue-agnostic? A: Its activity depends on an NTRK fusion rather than tumor origin, so the same agent serves lung, sarcoma, or salivary tumors that carry the fusion.

Q: Does entrectinib reach brain metastases? A: Yes, entrectinib penetrates the CNS, which supports intracranial disease control in ROS1-positive lung cancer.

Q: Which test guides entrectinib use? A: Broad next-generation sequencing to detect NTRK or ROS1 rearrangements is the standard prerequisite before therapy.